Back to dashboard
CommercialCoverageLow impact

08.01.34d, Exon Skipping Drugs for Duchenne Muscular Dystrophy (DMD) (Eteplirsen (Exondys 51), Golodirsen (Vyondys 53), Viltolarsen (Viltepso), Casimersen (Amondys 45))

Independence Blue Cross·Neurology, Pediatrics·Pharmacy
Effective date
Oct 29, 2025
We identified it
Jun 19, 2026
Days to comply
—

Summary

This is a reissue of an existing policy covering exon skipping drugs for Duchenne Muscular Dystrophy (DMD) including Eteplirsen, Golodirsen, Viltolarsen, and Casimersen. The policy has been updated for commercial plans with an effective date of October 29, 2025.

Action Required

Action needed
By October 29, 2025: Review updated policy requirements for DMD exon skipping drug coverage and prior authorization processes. Billing team should verify current procedures align with reissued policy guidelines for commercial patients requiring these specialty medications.

Related policy hubs